Design Therapeutics, Inc.

NASDAQ:DSGN

Biotechnology

Healthcare
$9.47 +1.59%

+$0.19 today

Market cap
$606.42M
Beta
1.66
P/E (TTM)
-10.7
EPS (TTM)
-$1.13
52W Low $3.33High $17.25

Volume 0.32M

Average 0.74M

DSGN Common Stock Issued

Cash raised by issuing new shares.

Design Therapeutics, Inc.NASDAQ: DSGN

Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026

Common stock issued growth accelerates

Q1 FY2026 common stock issued of $19.91M rose 86452.2% year over year, ahead of the +8741.5% change in trailing-twelve-month common stock issued. Sequentially, it fell 21.4% from the prior quarter. Over 3 fiscal years it compounded at +238.8% a year.

Context

  • Common stock issued increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +86452.2% holds above the trailing-twelve-month pace of +8741.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$19.91M-21.4% QoQ
Last fiscal yearDec 2025
$25.74M+4917.2% YoY
LTMMar 2026
$45.62M+8741.5% YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+86452.2%——
1 year+4917.2%——
3-year CAGR+238.8%——
5-year CAGR——
10-year CAGR——

Common Stock Issued history

USD · from the cash flow

Latest · FY2025
25.74M USD
Year-over-year change
+4917.2%
4-year CAGR
-43.6%

Common Stock Issued vs competitors

How DSGN compares with its peers on the latest reported figures

  • DSGN's LTM Mar 2026 common stock issued of $45.62M is the 10th largest of the 11 companies compared; the peer median is $176.77M.
  • Its year-over-year change of +8741.5% is the 3rd highest of 10, against a peer median of +147.9%.
  • Over three fiscal years its annual growth of +238.8% compares with a peer median of +29.0%.
DSGN Competitors Peer median
Common Stock Issued for DSGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DYNDyne Therapeutics, Inc.LTM Jun 2026$599.63M +265.0%+172.1%—
WVEWave Life Sciences Ltd.LTM Mar 2026$486.47M +117.8%+110.5%677.6%
SLDBSolid Biosciences Inc.LTM Mar 2026$244.85M +19.3%+39.0%—
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$211.21M +147.9%+211.5%22.0%
STOKStoke Therapeutics, Inc.LTM Mar 2026$180.34M +39.9%+29.0%562.2%
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$173.2M +62179.2%-4.7%—
FULCFulcrum Therapeutics, Inc.LTM Mar 2026$168.69M +15305.3%+27.8%—
PEPGPepGen Inc.LTM Mar 2026$109.49M +6044.2%-1.8%—
PTCTPTC Therapeutics, Inc.LTM Jun 2026$102.13M +121.2%+25.6%10.1%
DSGNDesign Therapeutics, Inc.LTM Mar 2026$45.62M +8741.5%+238.8%—
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$20.44M ——0.9%
Peer median (excluding DSGN) $176.77M+147.9%+29.0%22.0%

Competitors are the stored peer set for DSGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(35.53M)(63.31M)(66.86M)(49.59M)(69.79M)
Depreciation & Amortization129K406K537K596K(2.63M)
Deferred Income Tax00000
Stock-Based Compensation4.69M10.93M13.09M13.07M14.55M
Change in Working Capital1.4M1.99M728K(993K)3.11M
Accounts Receivables00000
Inventory00000
Accounts Payables2.41M5.39M(1.25M)(1.22M)4.49M
Other Working Capital(1.02M)(3.39M)1.97M226K(1.38M)
Other Non-Cash Items(58K)(1.33M)(6.05M)(6.19M)406K
Operating Cash Flow(29.38M)(51.32M)(58.56M)(43.11M)(54.36M)
Capital Expenditures(1.54M)(918K)(256K)(340K)(193K)
Acquisitions (Net)52.11K39K000
Purchases of Investments(86.26M)(313M)(224.7M)(230.18M)(291.78M)
Sales of Investments34.16M92.89M277.5M274.47M314.89M
Other Investing Activities(52.11K)0000
Investing Cash Flow(53.64M)(220.99M)52.54M43.96M22.91M
Debt Repayment00000
Common Stock Issued254.27M662K724K513K25.74M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities228K(427K)000
Financing Cash Flow379.21M235K724K513K25.74M
Effect of Forex Changes00000
Net Change in Cash296.19M(272.07M)(5.3M)1.36M(5.71M)
Free Cash Flow(30.92M)(52.24M)(58.82M)(43.45M)(54.55M)

Design Therapeutics, Inc.

NASDAQ:DSGN

Intrinsic Alpha fair value

Locked

Current Price

$9.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.